Aravive Valuation
Is VE11 undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
2/6Valuation Score 2/6
Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of VE11 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate VE11's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate VE11's fair value for valuation analysis.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for VE11?
Key metric: As VE11 is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.
| What is VE11's PS Ratio? | |
|---|---|
| PS Ratio | 0.4x |
| Sales | US$6.99m |
| Market Cap | US$2.95m |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | n/a |
| Enterprise Value/EBITDA | n/a |
| PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does VE11's PS Ratio compare to its peers?
| Company | Forward PS | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 2x | ||
CNW co.don | 0.7x | n/a | €6.5m |
SBH Sangui Biotech International | 3.8x | n/a | €419.8k |
BPXA Bellicum Pharmaceuticals | 0.5x | n/a | €772.4k |
MDG1 Medigene | 3x | 16.1% | €22.6m |
VE11 Aravive | 0.4x | n/a | €2.9m |
Price-To-Sales vs Peers: VE11 is good value based on its Price-To-Sales Ratio (0.4x) compared to the peer average (2.1x).
Price to Sales Ratio vs Industry
How does VE11's PS Ratio compare vs other companies in the DE Biotechs Industry?
Price-To-Sales vs Industry: VE11 is good value based on its Price-To-Sales Ratio (0.4x) compared to the European Biotechs industry average (8.7x).
Price to Sales Ratio vs Fair Ratio
What is VE11's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PS Ratio | 0.4x |
| Fair PS Ratio | n/a |
Price-To-Sales vs Fair Ratio: Insufficient data to calculate VE11's Price-To-Sales Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.
Discover undervalued companies
Perrigo
US$3.7b
Provides over-the-counter health and wellness solutions to enhance individual well-being in the United States, Europe, and internationally.
PIG
US$25.74
7D
1.9%
1Y
-7.4%
Aspen Pharmacare Holdings
R75.5b
Manufactures and supplies specialty and branded pharmaceutical products worldwide.
LDZA
R8.95
7D
0.6%
1Y
4.7%
Merck
US$252.6b
Operates as a healthcare company worldwide.
6MK
US$97.10
7D
6.7%
1Y
3.9%